Eisbach Bio positions HRD-targeting therapy to supplant PARP inhibitors
Eisbach Bio plans to use a $4.75m grant to advance EIS-12656, a small molecule ALC1 inhibitor to disrupt the genome …
Post
-
-
StemVacs-V by Res Nova Bio for Metastatic Breast Cancer: Likelihood of Approval
StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer. According to …
-
Lidocaine by MEDRx for Postherpetic Neuralgia: Likelihood of Approval
Lidocaine is under clinical development by MEDRx and currently in Pre-Registration for Postherpetic Neuralgia. According to GlobalData, Pre-Registration drugs for …
-
KGYY-15 by Op-T-Mune for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval
KGYY-15 is under clinical development by Op-T-Mune and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes). According to …
-
Tricaprilin by Cerecin for Infantile Spasm (West Syndrome): Likelihood of Approval
Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome). According to GlobalData, …
-
Gene Therapy to Target GD2 for Oncology by Bristol-Myers Squibb for Osteosarcoma: Likelihood of Approval
Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for …
-
Gene Therapy to Target GD2 for Oncology by Bristol-Myers Squibb for Sarcomas: Likelihood of Approval
Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for …
-
Nelivaptan by HMNC for Major Depressive Disorder: Likelihood of Approval
Nelivaptan is under clinical development by HMNC and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase …
-
Darigabat by Cerevel Therapeutics for Seizures: Likelihood of Approval
Darigabat is under clinical development by Cerevel Therapeutics and currently in Phase II for Seizures. According to GlobalData, Phase II …
-
Allergen for Grass Pollen Allergy by Roxall Medizin for Grass Pollen Allergy: Likelihood of Approval
Allergen for Grass Pollen Allergy is under clinical development by Roxall Medizin and currently in Phase II for Grass Pollen …
-
Immune globulin (human) by Grifols for Tachycardia (Tachyarrhythmias): Likelihood of Approval
Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Tachycardia (Tachyarrhythmias). According to GlobalData, …
-
Prexigebersen by Bio-Path for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, …
-
Prexigebersen by Bio-Path for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, …
-
Prexigebersen by Bio-Path for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). …
-
CR-4056 by Rottapharm Biotech for Osteoarthritis Pain: Likelihood of Approval
CR-4056 is under clinical development by Rottapharm Biotech and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase …